Related Experiment Video
Updated: Nov 21, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
Bernard F Hearon1, Kyle N Redelman2, Georges C Elhomsy3
1Department of Orthopaedics, University of Kansas School of Medicine, Wichita, Kansas, USA.
Abstract:
The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-related endocrinopathies, complete metabolic response on interim PET/CT scan was achieved. Two years after initial diagnosis, unifocal tumor reactivation was addressed with successful pembrolizumab monotherapy rechallenge. Immunotherapy, typically not used as frontline treatment for malignant pleural mesothelioma, may provide an effective and durable response for some patients. Based on this single case study, epithelioid type tumors with strongly positive PD-L1 and BAP1-negative immunohistochemical markers may be well suited for treatment with immune checkpoint inhibitors such as pembrolizumab.
More Related Videos
Related Concept Videos
Pleural Disorders: Types and Brief Description
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

